Search Result

Pathways Recommended:	Membrane Transporter/Ion Channel

Results for "

cardiac channel

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (6) Adenylate Cyclase (2) Adrenergic Receptor (4) Akt (2) Antibiotic (4) Apoptosis (4) Arrestin (1) Autophagy (12) Bacterial (6) Biochemical Assay Reagents (1) Calcium Channel (60) Calmodulin (3) CaMK (2) Chloride Channel (1) CRAC Channel (2) Cytochrome P450 (5) Dopamine Receptor (3) Drug Intermediate (1) Drug Metabolite (9) Endogenous Metabolite (1) Environmental Pollutants (1) Eukaryotic Initiation Factor (eIF) (1) Ferroptosis (3) HCN Channel (8) Histone Methyltransferase (1) Indoleamine 2,3-Dioxygenase (IDO) (1) Isotope-Labeled Compounds (17) mAChR (3) MMP (6) Monoamine Oxidase (2) Na+/Ca2+ Exchanger (2) nAChR (1) Opioid Receptor (3) Parasite (3) Phosphodiesterase (PDE) (5) PKA (3) Potassium Channel (61) PPAR (1) Reactive Oxygen Species (ROS) (3) Reference Standards (31) SARS-CoV (4) Serotonin Transporter (3) Sodium Channel (40) TGF-beta/Smad (6) TRP Channel (4) Urotensin Receptor (1)
By Research Areas:	Cancer (41) Cardiovascular Disease (131) Endocrinology (4) Infection (12) Inflammation/Immunology (8) Metabolic Disease (13) Neurological Disease (45)

By Targets:

5-HT Receptor (6)

Adenylate Cyclase (2)

Adrenergic Receptor (4)

Akt (2)

Antibiotic (4)

Apoptosis (4)

Arrestin (1)

Autophagy (12)

Bacterial (6)

Biochemical Assay Reagents (1)

Calcium Channel (60)

Calmodulin (3)

CaMK (2)

Chloride Channel (1)

CRAC Channel (2)

Cytochrome P450 (5)

Dopamine Receptor (3)

Drug Intermediate (1)

Drug Metabolite (9)

Endogenous Metabolite (1)

Environmental Pollutants (1)

Eukaryotic Initiation Factor (eIF) (1)

Ferroptosis (3)

HCN Channel (8)

Histone Methyltransferase (1)

Indoleamine 2,3-Dioxygenase (IDO) (1)

Isotope-Labeled Compounds (17)

mAChR (3)

MMP (6)

Monoamine Oxidase (2)

Na+/Ca2+ Exchanger (2)

nAChR (1)

Opioid Receptor (3)

Parasite (3)

Phosphodiesterase (PDE) (5)

PKA (3)

Potassium Channel (61)

PPAR (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (31)

SARS-CoV (4)

Serotonin Transporter (3)

Sodium Channel (40)

TGF-beta/Smad (6)

TRP Channel (4)

Urotensin Receptor (1)

By Research Areas:

Cancer (41)

Cardiovascular Disease (131)

Endocrinology (4)

Infection (12)

Inflammation/Immunology (8)

Metabolic Disease (13)

Neurological Disease (45)

165

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0284

Nifedipine 25+ Cited Publications BAY-a-1040	Calcium Channel Autophagy	Cardiovascular Disease Cancer
Nifedipine (BAY-a-1040) is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.

HY-107754

Cesium chloride	Potassium Channel	Cardiovascular Disease
Cesium chloride is a blocker of potassium channel. Cesium chloride prevents the decrease of Na ⁺ transport produced by Alloxan . Cesium chloride has induced cardiac arrhythmias, including torsade de pointes in animal models .

HY-B0252

Hydrochlorothiazide 5+ Cited Publications HCTZ	TGF-beta/Smad Potassium Channel	Cardiovascular Disease Metabolic Disease Cancer
Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B0632

Diltiazem 5+ Cited Publications	Calcium Channel	Cardiovascular Disease Cancer
Diltiazem is an orally active L-type Ca ²⁺ channel blocker. Diltiazem shows antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris .

HY-B0162A

Ivabradine hydrochloride 3 Publications Verification	HCN Channel	Cardiovascular Disease Infection Neurological Disease Metabolic Disease Cancer
Ivabradine hydrochloride is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine hydrochloride reduces dose-dependently heart rate without modification of blood pressure. Ivabradine hydrochloride shows anticonvulsant, anti-ischaemic and anti-anginal activity .

HY-17429

Flecainide acetate 3 Publications Verification R-818	Sodium Channel	Cardiovascular Disease
Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.

HY-12515

Nicardipine 5+ Cited Publications YC-93 free base	Calcium Channel	Cardiovascular Disease Neurological Disease Cancer
Nicardipine (YC-93 free base) is a calcium channel blocker with an IC₅₀ of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure .

HY-W010950

Flecainide 3 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-12515A

Nicardipine hydrochloride 5+ Cited Publications YC-93	Calcium Channel Autophagy	Cardiovascular Disease Neurological Disease Cancer
Nicardipine hydrochloride (YC-93) is a calcium channel blocker with an IC₅₀ of 1 μM for blocking cardiac calcium channels. Nicardipine hydrochloride acts as an agent for chronic stable angina and for controlling blood pressure .

HY-19765

GSK2798745 5+ Cited Publications	TRP Channel	Cardiovascular Disease
GSK2798745 is a potent, selective, and orally active transient receptor potential vanilloid 4 (TRPV4) ion channel blocker with IC₅₀s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively. GSK2798745 can be used in cardiac and respiratory diseases research .

HY-103192

MDL12330A 5 Publications Verification RMI12330A	Adenylate Cyclase Potassium Channel	Neurological Disease Cancer
MDL12330A (RMI12330A) is an adenylyl cyclases inhibitor. MDL12330A can inhibit K_V channels, increases insulin secretion and Ca ²⁺ levels. MDL12330A accentuates contractions in uterine rings and inhibits cardiac functions. MDL12330A can be used for the research of endocrinology, metabolic and cardiovascular disease .

HY-12533

Disopyramide 2 Publications Verification Dicorantil; SC-7031	Sodium Channel Potassium Channel	Cardiovascular Disease
Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .

HY-B0341

Nicorandil 1 Publications Verification SG-75	Potassium Channel	Cardiovascular Disease
Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K ⁺ channels and cardiac ATP-sensitive K ⁺ channels (K_ATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .

HY-18940A

Cilobradine hydrochloride DK-AH 269	HCN Channel	Cardiovascular Disease Neurological Disease
Cilobradine hydrochloride is a HCN channel blocker. Cilobradine hydrochloride induces cardiac pacemaker currents and produces antidepressant effects .

HY-15292

S107 1 Publications Verification	Calcium Channel	Cardiovascular Disease
S107 is an orally available, blood brain barrier-permeable compound, which stabilizes RyR2 channels by enhancing the binding of calstabin 2 to the mutant Ryr2-R2474S channel. S107 inhibits Ca ²⁺ leakage from the sarcoplasmic reticulum (SR) and prevents cardiac arrhythmias and raises the seizure threshold .

HY-B0162

Ivabradine 3 Publications Verification	HCN Channel	Cardiovascular Disease Cancer
Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity .

HY-122605

TRPM4-IN-1 CBA	TRP Channel	Cardiovascular Disease Cancer
TRPM4-IN-1 (CBA) is a potent and selective inhibitor of the cation channel TRPM4, with an IC₅₀ of 1.5 μM. TRPM4-IN-1 can be used for the research of cardiac diseases and prostate cancer .

HY-111747

TBAJ-587 3 Publications Verification	Bacterial	Infection Cardiovascular Disease
TBAJ-587, a potent anti-tuberculosis agent, inhibits M.tb strain H37Rv growth with MIC₉₀s of 0.006 and <0.02 μg/mL in MABA and LORA assay, respectively. TBAJ-587 inhibits hERG channel minimally, attenuates inhibition of the cardiac potassium channel protein coded by the hERG, which is important for cardiac repolarization .

HY-12533A

Disopyramide phosphate 2 Publications Verification Dicorantil phosphate; SC-7031 phosphate	Potassium Channel Sodium Channel	Cardiovascular Disease
Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .

HY-116838

TAM-16	Bacterial	Infection
TAM-16 is a potent and orally active polyketide synthase 13 (Pks13) inhibitor with an IC₅₀ value of 0.32 μM. TAM-16 has promising activity against Mycobacterium tuberculosis. TAM-16 inhibits hERG cardiac ion channel .

HY-W010950A

Flecainide hydrochloride 3 Publications Verification	Potassium Channel Sodium Channel	Cardiovascular Disease
Flecainide hydrochloride is an orally active antiarrhythmic agent. Flecainide hydrochloride can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide hydrochloride can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-14834A

Budiodarone tartrate ATI-2042 tartrate	Potassium Channel Sodium Channel Calcium Channel	Cardiovascular Disease
Budiodarone (ATI-2042) tartrate is a chemical analogue of Amiodarone (HY-14187) with balanced, multiple cardiac ion channel (potassium, sodium and calcium channels) inhibiting activity. Budiodarone tartrate is an antiarrhythmic agent .

HY-B1440

Ethaverine hydrochloride	Calcium Channel Monoamine Oxidase	Cardiovascular Disease
Ethaverine hydrochloride, a derivative of papaverine, inhibits cardiac L-type calcium channel. Ethaverine hydrochloride is a peripheral vasodilator and antispasmodic agent. Ethaverine hydrochloride can be used for research of peripheral vascular disease .

HY-16952A

Bepridil hydrochloride hydrate 5+ Cited Publications (±)-Bepridil hydrochloride hydrate; Org 5730 hydrochloride hydrate	Calcium Channel	Cardiovascular Disease
Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate) is a non-selective, long-acting Ca ⁺ channel antagonist and Na ⁺, K ⁺ channel inhibitor, with antianginal and type I antiarrhythmic effects. Bepridil hydrochloride hydrate also acts as a cardiac Na ⁺/Ca2 ⁺ exchange (NCX1) inhibitor. Bepridil hydrochloride hydrate can be used for the research of cardiovascular disorders .

HY-W001294

(R)-(-)-N-Boc-3-pyrrolidinol	Biochemical Assay Reagents Drug Intermediate	Cardiovascular Disease
(R)-(-)-N-Boc-3-pyrrolidinol (Compound 22a) is a key intermediate for the preparation of Compound 18a and subsequent ion channel modulating compounds. (R)-(-)-N-Boc-3-pyrrolidinol can be used in the research of cardiac arrhythmia .

HY-124702

ICA-105574 1 Publications Verification	Potassium Channel	Cardiovascular Disease
ICA-105574 is a potent and efficacious hERG channel activator. The primary mechanism by which ICA-105574 potentiates hERG channel activity is by removing hERG channel inactivation. ICA-105574 steeply potentiates current amplitudes more than 10-fold with an EC₅₀ value of 0.5 +/- 0.1 μM and a Hill slope (n(H)) of 3.3 +/- 0.2. ICA-105574 can prevent arrhythmias induced by cardiac delayed repolarization. ICA-105574 shortens action potential duration in ventricular myocytes concentration-dependently .

HY-135746

OR-1896 2 Publications Verification	Potassium Channel Phosphodiesterase (PDE) Drug Metabolite Apoptosis	Cardiovascular Disease
OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K ⁺ channels and has Ca ²⁺-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .

HY-108591

L-364,373 R-L3	Potassium Channel	Cardiovascular Disease
L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes .

HY-W019726

Dehydro Nifedipine BAY-b 4759	Drug Metabolite	Cardiovascular Disease Cancer
Dehydro nifedipine (BAY-b 4759) is a metabolite of Nifedipine (HY-B0284). Nifedipine (BAY-a-1040) is a potent calcium channel blocker and an agent of choice for cardiac insufficiencies .

HY-B0284R

Nifedipine (Standard) BAY-a-1040 (Standard)	Reference Standards Calcium Channel Autophagy	Cardiovascular Disease Cancer
Nifedipine (Standard) is the analytical standard of Nifedipine. This product is intended for research and analytical applications. Nifedipine (BAY-a-1040) is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.

HY-103059

SOICR-IN-1	Calcium Channel	Cardiovascular Disease
SOICR-IN-1 (compound 32) is a store-overload induced calcium release (SOICR) inhibitor with an IC₅₀ value of 14.6 μM. SOICR-IN-1 can be used for the research of cardiac arrhythmias .

HY-119747

WAY-123223	Potassium Channel	Cardiovascular Disease
WAY-123223 is an orally active potassium channel (Potassium Channel) blocker. WAY-123223 prolongs the transmembrane action potential duration and cardiac refractory period of canine Purkinje fibers. In canine models, WAY-123223 increases the ventricular fibrillation threshold, restores sinus rhythm from ventricular fibrillation, and exerts antiarrhythmic effects. WAY-123223 can be used in research related to cardiovascular diseases such as arrhythmias .

HY-A0236

Aprindine	Sodium Channel Potassium Channel Calcium Channel Calmodulin	Cardiovascular Disease
Aprindine is an Ib-class anti-arrhythmic agent. Aprindine mainly exerts its effect by blocking sodium channels (I_Na), thereby reducing the excitability and conduction velocity of cardiac muscle cells. Aprindine significantly inhibits delayed potassium currents, which helps to prolong the atrial effective refractory period (AERP) and inhibit the occurrence of atrial fibrillation. Aprindine can also regulate intracellular calcium ion concentration by inhibiting Na ⁺/Ca ²⁺ exchange current (INCX), thereby further stabilizing cardiac electrical activity. Aprindine can be used for the study of atrial fibrillation (AF) and ventricular arrhythmias .

HY-135356

m-Nifedipine	Drug Metabolite	Cardiovascular Disease
m-Nifedipine is an impurity of Nifedipine (BAY-a-1040). Nifedipine is a potent calcium channel blocker and agent of choice for cardiac insufficiencies .

HY-B0341S

Nicorandil-d4	Isotope-Labeled Compounds Potassium Channel	Cardiovascular Disease
Nicorandil-d₄ (SG-75-d₄) is the deuterium labeled Nicorandil. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K+ channels and cardiac ATP-sensitive K+ channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .

HY-120774

GS-462808	Sodium Channel	Cardiovascular Disease
GS-462808 is an oral active late sodium current inhibitor (Late INai) of the cardiac Nav1.5 channel with the IC₅₀ of 1.33 μM. GS-462808 can be used for study of arrhythmia .

HY-108592

UCL 2077	Potassium Channel	Cardiovascular Disease Neurological Disease
UCL 2077 is a potassium channel and slow afterhyperpolarization (sAHP) inhibitor. UCL 2077 selectively blocks sAHP channels without affecting L-type Ca ²⁺ currents. UCL 2077 blocks KCNQ1- and KCNQ2-containing K ⁺ channels, decreases erg current amplitude, increases erg deactivation rate. UCL 2077 can be used for the research of hippocampus-dependent memory retrieval deficit and cardiac arrhythmias .

HY-A0236A

Aprindine hydrochloride	Sodium Channel Potassium Channel Calcium Channel Calmodulin	Cardiovascular Disease
Aprindine hydrochloride is an Ib-class anti-arrhythmic agent. Aprindine hydrochloride mainly exerts its effect by blocking sodium channels (I_Na), thereby reducing the excitability and conduction velocity of cardiac muscle cells. Aprindine hydrochloride significantly inhibits delayed potassium currents, which helps to prolong the atrial effective refractory period (AERP) and inhibit the occurrence of atrial fibrillation. Aprindine hydrochloride can also regulate intracellular calcium ion concentration by inhibiting Na ⁺/Ca ²⁺ exchange current (INCX), thereby further stabilizing cardiac electrical activity. Aprindine hydrochloride can be used for the study of atrial fibrillation (AF) and ventricular arrhythmias .

HY-105454

Recainam Wy-42362	Sodium Channel	Cardiovascular Disease
Recainam (Wy-42362) is a potent orally active antiarrhythmic agent and a sodium channel inhibitor. Recainam elevates ventricular fibrillation threshold, suppresses induced cardiac dysrhythmias, and may accentuate cardiac tissue refractoriness heterogeneity. Recainam can be used for the research of arrhythmias .

HY-105084A

Lubeluzole dihydrochloride	Sodium Channel Calcium Channel	Cardiovascular Disease Infection Neurological Disease Cancer
Lubeluzole dihydrochloride is the dihydrochloride salt of Lubeluzole (HY-105084). Lubeluzole dihydrochloride is the S-isomer of benzothiazole derivative. Lubeluzole dihydrochloride can inhibit glutamate release, glutamate-activated NO synthesis and block voltage-gated Sodium Channel and Calcium Channel. Lubeluzole dihydrochloride exhibits anti-ischemic and neuroprotective effects. Lubeluzole dihydrochloride also shows anti-bacterial and anti-diarrheal potential. Lubeluzole dihydrochloride can inhibit cardiac sodium channel and prolong cardiac action potential. Lubeluzole dihydrochloride can inhibit cancer cells proliferation and invasion and shows chemosensitizing effect. Lubeluzole dihydrochloride can be used for the researches of cancer, infection, neurological and cardiovascular disease such as stroke, infectious diarrhea and ovarian .

HY-W010950S

Flecainide-d3	Potassium Channel Sodium Channel Isotope-Labeled Compounds	Cardiovascular Disease
Flecainide-d₃ is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-177361

Zocainone	Sodium Channel	Cardiovascular Disease
Zocainone is an antiarrhythmic agent. Zocainone blocks sodium channels in cardiac tissue, stabilizing the cardiac action potential and reducing abnormal electrical activity. Zocainone is promising for research of cardiac arrhythmias .

HY-P1219

Jingzhaotoxin-III β-TRTX-Cj1α	Sodium Channel	Neurological Disease
Jingzhaotoxin-III is a potent and selective blocker of Nav1.5 channels, with an IC₅₀ of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype .

HY-105084

Lubeluzole	Sodium Channel Calcium Channel	Infection Cardiovascular Disease Neurological Disease Cancer
Lubeluzole is the S-isomer of benzothiazole derivative. Lubeluzole can inhibit glutamate release, glutamate-activated NO synthesis and block voltage-gated Sodium Channel and Calcium Channel. Lubeluzole exhibits anti-ischemic and neuroprotective effects. Lubeluzole also shows anti-bacterial and anti-diarrheal potential. Lubeluzole can inhibit cardiac sodium channel and prolong cardiac action potential. Lubeluzole can inhibit cancer cells proliferation and invasion and shows chemosensitizing effect. Lubeluzole can be used for the researches of cancer, infection, neurological and cardiovascular disease such as stroke, infectious diarrhea and ovarian .

HY-B0632S

Diltiazem-d6	Isotope-Labeled Compounds Calcium Channel	Cardiovascular Disease
Diltiazem-d₆ is the deuterium labeled Diltiazem. Diltiazem is an orally active L-type Ca2+ channel blocker, with antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris .

HY-17429S

Flecainide-d4 acetate R-818-d₄	Sodium Channel	Cardiovascular Disease
Flecainide-d₄ (acetate) is the deuterium labeled Flecainide acetate. Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential .

HY-P4898

Anthopleurin-A	Sodium Channel	Cardiovascular Disease
Anthopleurin-A is a soidum channel toxin. Anthopleurin-A is selective for cardiac channels and has cardiotonic effect. Anthopleurin-A can be isolated from the sea anemone .

HY-P4898A

Anthopleurin-A TFA	Sodium Channel	Cardiovascular Disease
Anthopleurin-A TFA is a soidum channel toxin. Anthopleurin-A TFA is selective for cardiac channels and has cardiotonic effect. Anthopleurin-A TFA can be isolated from the sea anemone .

HY-P5772

Jingzhaotoxin-II	Sodium Channel	Neurological Disease
Jingzhaotoxin-II, a 32 amino acid residues including two acidic and two basic residues, is a neurotoxin. Jingzhaotoxin-II inhibits *voltage-gated sodium channels* (VGSC)** that significantly slows rapid inactivation of TTX-resistant (TTX-R) VGSC on cardiac myocytes with the IC₅₀ of 0.26 μM .

HY-W019726R

Dehydro Nifedipine (Standard) BAY-b 4759 (Standard)	Reference Standards Drug Metabolite	Cardiovascular Disease Cancer
Dehydro Nifedipine (Standard) is the analytical standard of Dehydro Nifedipine. This product is intended for research and analytical applications. Dehydro nifedipine (BAY-b 4759) is a metabolite of Nifedipine (HY-B0284). Nifedipine (BAY-a-1040) is a potent calcium channel blocker and an agent of choice for cardiac insufficiencies .

Cat. No.	Product Name

HY-L118

Sodium Channel Blocker Library

187 compounds

Sodium channels conduct sodium ions (Na+) through a cell's plasma membrane that are the source of excitatory currents for the nervous system and muscle. Na channels are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). Dysfunction in voltage-gated sodium channels correlates with neurological and cardiac diseases, including epilepsy, myopathies, pain and cardiac arrhythmias. Sodium channel blockers are used in the treatment of cardiac arrhythmia, pain and convulsion.

MCE offers a unique collection of 187 sodium channel blocker and antagonists, all of which have the identified inhibitory effect on sodium channels. MCE Sodium Channel Blocker Library can be used for neurological and cardiac diseases drug discovery and sodium channel research.

HY-L923

Ion Channel Lead-like Compound Library

9000 compounds

Ion channels are key proteins on the cell membrane that regulate the flow of ions across membranes. They participate in nearly all physiological processes, including nerve conduction, muscle contraction, heart rhythm, and pain perception. Abnormalities in their function can lead to various serious diseases such as arrhythmia, epilepsy, hypertension, neuropathic pain, and cancer. Therefore, ion channels are highly valuable drug targets—over 15% of approved drugs target ion channels currently, demonstrating their irreplaceable therapeutic value in cardiovascular, neurological, and analgesic fields.

MCE has collected a library of over 5,000 reported ion channel-related bioactive compounds targeting major sites such as Na+ channels, K+ channels, Ca2+ channels, GABA receptors, iGluRs, and others. Using AI models, these compounds are characterized through both 2D representations (molecular fingerprints, pharmacophores) and 3D representations (3D conformation) to screen for a collection of lead-like compounds highly similar to known active molecules. Additionally, an hERG channel prediction algorithm integrating XGB and ISE mapping strategy is employed to assess and exclude potential cardiotoxicity in the library.. This step significantly reduces safety risks in subsequent screenings, particularly for ion channel drug development related to cardiovascular systems (e.g., Nav1.5, Cav1.2), effectively minimizing failures due to hERG inhibition and serving as a valuable tool for ion channel drug screening.

HY-L225

Cardiotoxic Compound Library

258 compounds

Drug development is both expensive and time-consuming, with approximately one-third of drug discontinuations caused by severe adverse drug reactions (ADRs). Among these, drug-induced cardiotoxicity (DICT) is one of the primary reasons for late-stage clinical drug failures and market withdrawals. To date, cardiotoxicity has been observed in multiple drug classes, such as anticancer drugs, antipsychotics, antidepressants, antibiotics, and neurodegenerative disease medications. To reduce cardiac ADRs, it is crucial to determine the clinical relevance of DICT to treatment, elucidate the underlying molecular mechanisms, identify reliable biomarkers, and develop new diagnostic and therapeutic approaches.

MCE offers 258 cardiotoxicity compounds, including some FDA-approved drugs as well as inhibitors/blockers of the hERG potassium channel.

Cat. No.	Product Name	Type

HY-107754

Cesium chloride	Biochemical Assay Reagents
Cesium chloride is a blocker of potassium channel. Cesium chloride prevents the decrease of Na ⁺ transport produced by Alloxan . Cesium chloride has induced cardiac arrhythmias, including torsade de pointes in animal models .

HY-W001294

(R)-(-)-N-Boc-3-pyrrolidinol	Biochemical Assay Reagents
(R)-(-)-N-Boc-3-pyrrolidinol (Compound 22a) is a key intermediate for the preparation of Compound 18a and subsequent ion channel modulating compounds. (R)-(-)-N-Boc-3-pyrrolidinol can be used in the research of cardiac arrhythmia .

Cat. No.	Product Name	Target	Research Area

HY-P1219

Jingzhaotoxin-III β-TRTX-Cj1α	Sodium Channel	Neurological Disease
Jingzhaotoxin-III is a potent and selective blocker of Nav1.5 channels, with an IC₅₀ of 348 nM, and shows no effect on other sodium channel isoforms. Jingzhaotoxin-III can selectively inhibit the activation of cardiac sodium channel but not neuronal subtypes, and hopefully represents an important ligand for discriminating cardiac VGSC subtype .

HY-P4898

Anthopleurin-A	Sodium Channel	Cardiovascular Disease
Anthopleurin-A is a soidum channel toxin. Anthopleurin-A is selective for cardiac channels and has cardiotonic effect. Anthopleurin-A can be isolated from the sea anemone .

HY-P4898A

Anthopleurin-A TFA	Sodium Channel	Cardiovascular Disease
Anthopleurin-A TFA is a soidum channel toxin. Anthopleurin-A TFA is selective for cardiac channels and has cardiotonic effect. Anthopleurin-A TFA can be isolated from the sea anemone .

HY-P5772

Jingzhaotoxin-II	Sodium Channel	Neurological Disease
Jingzhaotoxin-II, a 32 amino acid residues including two acidic and two basic residues, is a neurotoxin. Jingzhaotoxin-II inhibits *voltage-gated sodium channels* (VGSC)** that significantly slows rapid inactivation of TTX-resistant (TTX-R) VGSC on cardiac myocytes with the IC₅₀ of 0.26 μM .

HY-P5319

MCaE12A	Calcium Channel	Others
MCaE12A is a high-affinity modulator of RyR2 and increases RyR2 sensitivity to cytoplasmic calcium concentrations promoting channel opening. MCaE12A acts as an important tool for RyR2 structure-to-function studies as well as for manipulating Ca2+ homeostasis and dynamic of cardiac cell .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1906

Streptomycin 45+ Cited Publications Agrept; Agrimycin; Streptomycin A	Microorganisms Source Classification	Environmental Pollutants Antibiotic Bacterial
Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .

HY-B1906R

Streptomycin (Standard) Agrept (Standard); Agrimycin (Standard); Streptomycin A (Standard)	Microorganisms Source Classification	Reference Standards Antibiotic Bacterial
Streptomycin (Standard) is the analytical standard of Streptomycin. This product is intended for research and analytical applications. Streptomycin (Agrept) is an effective antibiotic against M. tuberculosis, is used for the research of tuberculosis (TB). Streptomycin also is a bacteriocidal agent that can be used for the research of a number of bacterial infections. Streptomycin can bind strongly to nucleic acids, interferes and blocks protein synthesis while permitting continued RNA and DNA synthesis. Streptomycin, as a common antibiotic used in culture media, also is a blocker of stretch-activated and mechanosensitive ion channels in neurons and cardiac myocytes .

HY-W041470R

4-Methyl-1-phenyl-2-pentanone (Standard)	Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Chlorpromazine (hydrochloride) (Standard) is the analytical standard of Chlorpromazine (hydrochloride). This product is intended for research and analytical applications. Chlorpromazine hydrochloride is an orally active, blood-brain barrier-transparent antipsychotic agent that effectively antagonises D2 dopamine receptors and 5-HT2A, which is widely used in schizophrenia and other psychiatric disorders. Chlorpromazine hydrochloride exerts anti-cancer activity through a variety of pathways, including anti-proliferation, induction of autophagy and cycle arrest (G2-M phase), inhibition of cytochrome c oxidase (CcO), inhibition of tumour growth and metastasis, and inhibition of tumour immune escape. Chlorpromazine hydrochloride also blocks hNav1.7 channels (IC50=25.9 μM; concentration-dependent) and HERG potassium channels (IC50=21.6 μM), which has potential for analgesic and cardiac arrhythmic studies. Chlorpromazine hydrochloride also can inhibit clathrin-mediated endocytosis .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702228

	CACNA1C Protein, Pig (Cell-Free, His) Voltage-dependent L-type calcium channel subunit alpha-1C; Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle; Voltage-gated calcium channel subunit alpha Cav1.2	Pig	E. coli Cell-free
	The CACNA1C protein is the alpha-1C subunit of voltage-gated calcium channels that generate L-type calcium currents that are critical for calcium influx and sarcoplasmic release. Its role in excitation-contraction coupling is critical for cardiac development, rhythm regulation, and smooth muscle cell contraction. CACNA1C Protein, Pig (Cell-Free, His) is the recombinant pig-derived CACNA1C protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0252S1

Hydrochlorothiazid-13C,d2

Hydrochlorothiazid- ¹³C,d₂ is the ¹³C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B0341S

Nicorandil-d4
Nicorandil-d₄ (SG-75-d₄) is the deuterium labeled Nicorandil. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K+ channels and cardiac ATP-sensitive K+ channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases .

HY-B0252S

Hydrochlorothiazid-d2

Hydrochlorothiazid-d₂ is the deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-W052508S

Norquetiapine-d8

Norquetiapine-d8 (N-Desalkylquetiapine-d8) is the deuterium labeled Norquetiapine.Norquetiapine ( N-Desalkylauetiapine), a metabolite of Quetiapine (HY-14544), is a selective HCN1 channel inhibitor, with an IC₅₀ of 13.9 μM. Norquetiapine selectively inhibits noradrenaline reuptake, is a partial 5-HT_1A (K_i = 45 nM) receptor agonist, and acts as an antagonist at presynapticα2 (K_i = 237 nM), 5-HT_2C(K_i = 107 nM), and 5-HT₇ (K_i = 76 nM) receptors. Norquetiapine blocks the human cardiac sodium channel Nav1.5 in a state-dependent manner. Norquetiapine shows partial anti-inflammatory effects in LPS (HY-D1056) injected C57BL/6 mice. Norquetiapine can be used for the study of depression and inflammation .

HY-W010950S

Flecainide-d3
Flecainide-d₃ is the deuterium labeled Flecainide. Flecainide is an orally active antiarrhythmic agent. Flecainide can block sodium channels and inhibit calcium ion release mediated by the cardiac ryanodine receptor (RyR2). Flecainide can be used in the research of diseases such as catecholaminergic polymorphic ventricular tachycardia (CPVT) .

HY-B0252S3

Hydrochlorothiazide-15N2,13C,d2

Hydrochlorothiazide- ¹⁵N₂, ¹³C,d₂ is ¹⁵N and deuterated labeled Hydrochlorothiazide (HY-B0252). Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-B0632S

Diltiazem-d6
Diltiazem-d₆ is the deuterium labeled Diltiazem. Diltiazem is an orally active L-type Ca2+ channel blocker, with antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris .

HY-17429S

Flecainide-d4 acetate
Flecainide-d₄ (acetate) is the deuterium labeled Flecainide acetate. Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential .

HY-B0284S1

Nifedipine-d4
Nifedipine-d₄ is the deuterium labeled Nifedipine. Nifedipine (BAY-a-1040) is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.

HY-12515AS

Nicardipine-d3 hydrochloride
Nicardipine-d₃ hydrochloride (YC-93 D₃) is the deuterium labeled Nicardipine hydrochloride. Nicardipine hydrochloride is a calcium channel blocker with an IC₅₀ of 1 μM for blocking cardiac calcium channels. Nicardipine hydrochloride acts as an agent for chronic stable angina and for controlling blood pressure .

HY-12515AS2

Nicardipine-d4 hydrochloride
Nicardipine-d₄ hydrochloride is deuterated labeled Nicardipine hydrochloride (HY-12515A). Nicardipine hydrochloride (YC-93) is a calcium channel blocker with an IC₅₀ of 1 μM for blocking cardiac calcium channels. Nicardipine hydrochloride acts as an agent for chronic stable angina and for controlling blood pressure .

HY-B0284S2

Nifedipine-13C8
Nifedipine-13C8 is a deuterated labeled Nifedipine . Nifedipine (BAY-a-1040) is a potent calcium channel blocker and agent of choice for cardiac insufficiencies.

HY-B0632S2

Diltiazem-d4
Diltiazem-d₄ is deuterium labeled Diltiazem. Diltiazem is an orally active L-type Ca ²⁺ channel blocker. Diltiazem shows antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris .

HY-W019726S1

Dehydro Nifedipine-13C,d3
Dehydro Nifedipine-13C,d3 is a deuterated labeled Dehydro Nifedipine . Dehydro nifedipine (BAY-b 4759) is a metabolite of Nifedipine (HY-B0284). Nifedipine (BAY-a-1040) is a potent calcium channel blocker and an agent of choice for cardiac insufficiencies .

HY-B0162S

Ivabradine-d6
Ivabradine-d₆ is the deuterium labeled Ivabradine . Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity .

HY-B0252S2

Hydrochlorothiazide-13C6

Hydrochlorothiazide- ¹³C₆ is the ¹³C labeled Hydrochlorothiazide . Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect .

HY-106577S

Cibenzoline-d4

Cibenzoline-d₄ (Cifenline-d₄) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

HY-B0653AS

Levobupivacaine-d9 hydrochloride

Levobupivacaine-d₉ ((S)-(–)-Bupivacaie-d₉) hydrochloride is deuterium labeled Levobupivacaine hydrochloride (HY-B0653A). Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer .

HY-14744S

Levamlodipine-d4

Levamlodipine-d₄ is the deuterium labeled Levamlodipine. Levamlodipine ((S)-Amlodipine; Levoamlodipin) is an orally active L-type calcium channel blocker and MMP-9 modulator with high permeability and retention properties. Levamlodipine significantly enhances plaque stability and improves lipid profiles by reducing blood pressure, decreasing systolic blood pressure variability, and inhibiting MMP-9 expression in atherosclerotic plaques. Levamlodipine not only alleviates cardiac and aortic hypertrophy and prevents renal atrophy, but also produces synergistic effects in blood pressure reduction and organ protection when combined with bisoprolol (HY-129029). Levamlodipine exerts no significant inhibitory effect on abdominal aortic intimal hyperplasia. When excessively accumulated in the epidermis, Levamlodipine may induce changes in keratin structure, impair the skin barrier and trigger inflammation; long-term use further exacerbates skin irritation caused by local administration. Levamlodipine can be used in research related to hypertension and atherosclerosis .

HY-135746S

OR-1896-d3
OR-1896-d₃ is the deuterium labeled OR-1896 (HY-135746). OR-1896 is an active long-lived metabolite of Levosimendan. OR-1896 is a highly selective phosphodiesterase (PDE) III isoform inhibitor and a powerful vasodilator. OR-1896 can open ATP-sensitive K+ channels and has Ca2+-sensitizing effect. OR-1896 mitigates cardiomyocyte apoptosis, cardiac remodeling and myocardial inflammation .

HY-106577S1

Cibenzoline-d5

Cibenzoline-d₅ (Cifenline-d₅) is deuterium labeled Cibenzoline. Cibenzoline is a class Ia antiarrhythmic active molecule with low anticholinergic activity. Cibenzoline is a K_ATP channel inhibitor, acting through the pore forming subunit Kir6.2, with an IC₅₀ of 22.2 μM. Cibenzoline inhibits I_Kr and I_Ks currents with IC₅₀ values of 8.8 μM and 12.3 μM, respectively. Cibenzoline is used in the study of cardiac diseases. In addition, Cibenzoline can induce hypoglycemia .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86930

	KCNA5/KV1-5 Antibody (YA6623) ATFB7 antibody; cardiac potassium channel antibody; HCK1 antibody; HK2 antibody; HPCN1 antibody; insulinoma and islet potassium channel antibody; KCNA5 antibody; KCNA5_HUMAN antibody; KV1.5 antibody; PCN1 antibody; ATFB7 antibody; cardiac potassium channel antibody; HCK1 antibody; HK2 antibody; HPCN1 antibody; insulinoma and islet potassium channel antibody; KCNA5 antibody; KCNA5_HUMAN antibody; KV1.5 antibody; PCN1 antibody; potassium channel 1 antibody; Potassium channel, insulinoma and islet cell antibody; Potassium channel, voltage-gated, shaker-related subfamily, member 5 antibody; Potassium voltage gated channel subfamily A member 5 antibody; Potassium voltage-gated channel subfamily A member 5 antibody; Voltage-gated potassium channel HK2 antibody; voltage-gated potassium channel protein Kv1.5 antibody; Voltage-gated potassium channel subunit Kv1.5 antibody;	WB	Human, Mouse, Rat
	KCNA5/KV1-5 Antibody (YA6623) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to KCNA5/KV1-5.